Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | HPD | P32754 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097204 | 0.88 | ALDH1A1 (0.49) | MAOBCYP4F2CYP4A11NR4A2MAOA | |
| SCHEMBL13097250 | 0.82 | CHRNB2 (0.50) | — | |
| SCHEMBL13097251 | 0.82 | MAOB (0.38) | MAOBKMT2ASMN1; SMN2 | |
| SCHEMBL13107120 | 0.80 | GRIN1 (0.49) | KMT2A | |
| SCHEMBL6584414 | 0.77 | CYP4F2 (0.51) | MAOBCYP4F2CYP4A11NR4A2BCHE | |
| SCHEMBL3096144 | 0.77 | LTA4H (0.55) | MAOBBCHE | |
| SCHEMBL25517325 | 0.77 | CYP4F2 (0.58) | MAOBCYP4F2CYP4A11NR4A2BCHE | |
| SCHEMBL1268719 | 0.76 | MAOB (0.81) | MAOBCYP4F2CYP4A11NR4A2BCHE | |
| SCHEMBL4763643 | 0.76 | CYP4F2 (0.70) | MAOBCYP4F2CYP4A11NR4A2BCHE | |
| SCHEMBL3106679 | 0.74 | LTA4H (0.55) | MAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | MAOB 200/4885CYP4F2 333/4885CYP4A11 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.